Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

TP53 in hematological cancer: Low incidence of mutations with significant clinical relevance

TP53 in hematological cancer: Low incidence of mutations with significant clinical relevance Inactivation of the wild‐type p53 gene (TP53) by various genetic alterations is a major event in human tumorigenesis. More than 60% of human primary tumors exhibit a mutation in the p53 gene. Hematological malignancies present a rather low incidence of genetic alterations in this gene (10–20%). Nevertheless, epidemiological studies of the hematological malignancies indicate that the prognosis of patients with a mutation in the p53 gene is worse than those expressing the wild‐type p53 protein. Correlations between drug resistance, altered apoptosis, and mutations in the p53 gene are found in hematological malignancies and leukemias. These issues, as well as the possibility of exploiting p53 and its various functions for new therapeutic strategies, are discussed in the present review. Hum Mutat 21:277–284, 2003. © 2003 Wiley‐Liss, Inc. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Human Mutation Wiley

TP53 in hematological cancer: Low incidence of mutations with significant clinical relevance

Peller, Shoshana; Rotter, Varda
Human Mutation , Volume 21 (3) – Mar 1, 2003
Download PDF
8 pages

Loading next page...
 
/lp/wiley/tp53-in-hematological-cancer-low-incidence-of-mutations-with-QccxesPmkC

References (76)

Publisher
Wiley
Copyright
Copyright © 2003 Wiley Subscription Services, Inc., A Wiley Company
ISSN
1059-7794
eISSN
1098-1004
DOI
10.1002/humu.10190
pmid
12619113
Publisher site
See Article on Publisher Site

Abstract

Inactivation of the wild‐type p53 gene (TP53) by various genetic alterations is a major event in human tumorigenesis. More than 60% of human primary tumors exhibit a mutation in the p53 gene. Hematological malignancies present a rather low incidence of genetic alterations in this gene (10–20%). Nevertheless, epidemiological studies of the hematological malignancies indicate that the prognosis of patients with a mutation in the p53 gene is worse than those expressing the wild‐type p53 protein. Correlations between drug resistance, altered apoptosis, and mutations in the p53 gene are found in hematological malignancies and leukemias. These issues, as well as the possibility of exploiting p53 and its various functions for new therapeutic strategies, are discussed in the present review. Hum Mutat 21:277–284, 2003. © 2003 Wiley‐Liss, Inc.

Journal

Human Mutation – Wiley

Published: Mar 1, 2003

Keywords: hematological cancer; tumor; p53; TP53; drug resistance; leukemia; lymphoma

There are no references for this article.